In vitro fertilization is an assisted reproductive technology (ART), which involves retrieving eggs from a woman's ovaries and fertilizing them with sperm outside the body, in vitro. The Asia-Pacific IVF services revenue market generated $3,734 million in 2017 and is projected to reach $13,669 million by 2028, growing at a CAGR of 12.4% from 2018 to 2028.
The Asia-Pacific IVF services market is anticipated to exhibit significant market growth during the forecast period, owing to rise in infertility rate, increase in trend of delayed pregnancies, surge in IVF success rate, and rise in disposable income in the Asia-Pacific region. However, complications associated with IVF treatment, and low awareness level for IVF in some under developed regions hinder the growth of the market. Conversely, upsurge in fertility tourism, increase in number of fertility clinics, and growth opportunities in the emerging markets make way for market development in the future.
The Asia-Pacific IVF services market is segmented based on cycle type, end user, and country. Based on cycle type, the market is divided into fresh IVF cycle (non-donor), thawed IVF cycle (non-donor), and donor egg IVF cycle. According to end user, the market is classified as fertility clinics, hospitals, surgical centers and clinical research institutes. Country wise, the market is studied across India, China, Japan, Australia, New Zealand, South Korea, Thailand, Singapore, Malaysia, Indonesia, Philippines, Vietnam, Myanmar, and Rest of Asia-Pacific.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2028, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Cycle Type
Fresh IVF Cycles (Non-Donor)
Thawed IVF Cycles (Non-Donor)
Donor Egg IVF Cycles
By End User
Fertility Clinics
Hospitals
Surgical centers
Clinical research institutes
By Country
India
China
Japan
Australia
New Zealand
South Korea
Thailand
Singapore
Malaysia
Indonesia
Philippines
Vietnam
Myanmar
Rest of Asia-Pacific
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Apollo Hospitals Dhaka
Australian Concept Infertility Medical Center (ACIMC)
Bahosi Fertility Centre
Bangkok IVF center
Bloom Fertility and Healthcare
Bloom Fertility Center
Bourn Hall Fertility Center
Bumrungrad International Hospital
Center for Advanced Reproductive Medicine and Infertility
CHA Fertility Center
Chennai Fertility Center
Cloudnine Fertility
Damai Service Hospital
Fatemieh Infertility Center
Fertility Associates
Fertility Centre Nepal (Part of Wecare Health Services, India)
Fertility First
Flinders Reproductive Medicine Pty Ltd
Genea Oxford Fertility Limited
IHH Healthcare Berhad
IVF NAMBA Clinic
IVF Sri Lanka Life Plus (Pvt) Ltd
IVF Van Hanh
KL Fertility & Gynecology Centre
Lanka Hospitals
LIFE - Lahore Institute of Fertility & Endocrinology
Lotus Fertility Clinic
Manipal Fertility
Maria Fertility Hospital
MEHR IVF Clinic
Monash IVF Wesley Hospital Auchenflower
Morpheus Life Sciences Pvt. Ltd.
Morula IVF
National University Hospital
Nepal International Fertility Centre
Oak Medical Group/Oak Clinic
Raffles Medical Group
Repromed
RSUP Dr. Hasan Sadikin Bandung
SAFE Fertility Center
Sanno Hospital
Saqib Fertility & IVF Center - Mid City Hospital
Shanghai Ji Ai Genetics & IVF Institute
Shanghai United Family Hospital
Southend Fertility and IVF
Superior A.R.T Myanmar
Thomson Medical Pte. Ltd.
TMC Fertility Centre
Tu Du Hospital
Victory A.R.T. Laboratory Phils., Inc.
Virtus Health
